Browsing by Subject "Cancer combination chemotherapy"

Article

Adjuvant chemotherapy using CPT-11, leucovorin plus bolus 5-fluorouracil and radiotherapy in patients with rectal cancer. A feasibility study

Kalofonos, H. P.; Kardamakis, D.; Bamias, A. T.; Skarlos, Dimosthenis V.; Papakostas, P.; Bafaloukos, Dimitrios; Sakantamis, A.; Pavlidis, Nicholas; Fountzilas, George (2003)

Background: The addition of CPT-11 to 5FU/leucovorin resulted in survival benefit in patients with advanced colorectal cancer suggesting that this combination could be used successfully in the adjuvant setting. We studied ...

Article

Biweekly administration of 24-h infusion of irinotecan followed by a 1-h infusion of docetaxel: A phase I study

Briassoulis, E. Ch; Pentheroudakis, George; Timotheadou, H.; Rammou, D.; Pavlidis, Nicholas; Fountzilas, George (2004)

We developed a chemotherapy combination regimen based on preclinical data suggesting synchronization of cancer cells in G2/M phase when exposed to irinotecan over a protracted period. This phase I study aimed to determine ...

Article

Cancer and pregnancy: What should we know about the management with systemic treatment of pregnant women with cancer?

Pavlidis, Nicholas (2011)

The incidence of cancer during pregnancy is a rare phenomenon and is estimated to occur in 1:1000 pregnancies. This co-existence is likely to rise since the delay of childbearing to the later reproductive age is nowadays ...

Article

Cancer of unknown primary site

Pavlidis, Nicholas; Pentheroudakis, George (2012)

Cancer of unknown primary site (CUP) is a well recognised clinical disorder, accounting for 3-5 of all malignant epithelial tumours. CUP is clinically characterised as an aggressive disease with early dissemination. ...

Article

Cancer of unknown primary: Biological and clinical characteristics

Pavlidis, Nicholas (2003)

Article

Cancer of unknown primary: What kind of chemotherapy? what kind of disease?

Pentheroudakis, George; Pavlidis, Nicholas (2009)

Article

Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Fizazi, K.; Greco, F. A.; Pavlidis, Nicholas; Pentheroudakis, George (2011)

Article

Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study

Briassoulis, E. Ch; Kalofonos, H. P.; Bafaloukos, Dimitrios; Samantas, E.; Fountzilas, George; Xiros, N.; Skarlos, Dimosthenis V.; Christodoulou, C.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas (2000)

Purpose: To evaluate the efficacy of the carboplatin/paclitaxel combination in patients with carcinoma of unknown primary site (CUP). Patients and Methods: Seventy-seven consecutive CUP patients (45 women and 32 men; median ...

Article

Carcinoma of unknown primary (CUP)

Pavlidis, Nicholas; Fizazi, K. (2009)

Carcinoma of unknown primary (CUP) is one of the 10 most frequent cancers worldwide. It constitutes 3-5% of all human malignancies. Patients with CUP present with metastases without an established primary site. CUP manifests ...

Article

Carcinoma of unknown primary: Natural history and treatment. Analysis of 30 cases and review of the literature

Pavlidis, Nicholas; Sourla, A.; Ch, F. Tolis; Theoharis, N. M.; Nikolaou, N. (1990)

In this study, the natural history and therapeutic management of 30 patients with carcinoma of unknown primary (CUP syndrome) is presented. Despite detailed laboratory investigations, the primary occult tumor was not ...

Article

CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group

Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)

Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...

Article

Cisplatin/etoposide versus carboplatin/etoposide chemotherapy and irradiation in small cell lung cancer: A randomized phase III study

Kosmidis, Paraskevas A.; Samantas, E.; Fountzilas, George; Pavlidis, Nicholas; Apostolopoulou, F.; Skarlos, Dimosthenis V. (1994)

The efficacy and toxicity of cisplatin/etoposide and carboplatin/etoposide combinations along with thoracic irradiation were prospectively assessed in patients with small cell lung cancer. Both combinations were equally ...

Article

Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group

Papageorgiou, E.; Tsirigotis, P.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Papageorgiou, S.; Economopoulos, T. (2005)

To investigate the efficacy and toxicity of the combination of gemcitabine and vinorelbine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL), 22 patients with relapsed or refractory DLBL were ...

Article

Combination chemotherapy with paclitaxel and gemcitabine followed by concurrent chemoradiotherapy in non-operable localized non-small cell lung cancer. A Hellenic Cooperative Oncology Group (HeCOG) phase II study

Kosmidis, Paraskevas A.; Fountzilas, George; Baka, S.; Samantas, E.; Dimopoulos, M. A.; Gogas, H.; Skarlos, Dimosthenis V.; Papacostas, P.; Boukovinas, I.; Bakoyiannis, Chris; Pantelakos, P.; Athanassiou, E.; Misailidou, D.; Tsekeris, P.; Pavlidis, Nicholas (2007)

Concurrent chemoradiotherapy has become a standard therapy for locoregionally advanced inoperable non-small cell lung cancer (NSCLC). The purpose of this phase II trial was to evaluate the efficacy and toxicity of concurrent ...

Article

Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: A phase III randomized study. Preliminary results

Kosmidis, Paraskevas A.; Mylonakis, N.; Dimopoulos, M. A.; Pavlidis, Nicholas; Fountzilas, George; Samantas, E.; Dimitriadis, K.; Kalofonos, H. P.; Tsavdaridis, D.; Skarlos, Dimosthenis V. (2000)

Gemcitabine plus paclitaxel and paclitaxel plus carboplatin are active and well tolerated in patients with advanced non-small cell lung cancer, showing similar rates of response and survival. The Hellenic Cooperative ...

Article

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: First report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

Fountzilas, George; Dafni, U.; Papadimitriou, C.; Timotheadou, E.; Gogas, H.; Eleftheraki, A. G.; Xanthakis, I.; Christodoulou, C.; Koutras, A. K.; Papandreou, C. N.; Papakostas, P.; Miliaras, S.; Markopoulos, C.; Dimitrakakis, C.; Korantzopoulos, Panagiotis; Karanikiotis, C.; Bafaloukos, Dimitrios; Kosmidis, Paraskevas A.; Samantas, E.; Varthalitis, I.; Pavlidis, Nicholas; Pectasides, Dimitrios; Dimopoulos, M. A. (2014)

Background: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of ...

Article

Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the hellenic cooperative oncology group

Fountzilas, George; Papadimitriou, C.; Dafni, U.; Bafaloukos, Dimitrios; Skarlos, Dimosthenis V.; Moulopoulos, L. A.; Razi, E. D.; Kalofonos, H. P.; Aravantinos, Gerasimos; Briassoulis, E. Ch; Papakostas, P.; Abela, K.; Gogas, H.; Kosmidis, Paraskevas A.; Pavlidis, Nicholas; Dimopoulos, M. A. (2001)

Purpose: To compare the efficacy of two different schedules of epirubicin and paclitaxel, as first-line chemotherapy, in patients with advanced breast cancer (ABC). Patients and Methods: From October 1997 until May 1999, ...

Article

ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of cancers of unknown primary site (CUP)

Briassoulis, E. Ch; Ch, F. Tolis; Pavlidis, Nicholas (2001)

Article

Favorable outcome in non-Hodgkin lymphoma of the maxillary sinus treated with R-CHOP

Doumas, Stergios; Sakkas, L.; Panayiotidis, P.; Wozniak, Greta; Vlychou, M.; Vassilopoulos, G. (2014)

Article

Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: Analysis of a prospective randomized phase III trial

Kosmidis, Paraskevas A.; Tsavaris, N.; Skarlos, Dimosthenis V.; Theocharis, D.; Samantas, E.; Pavlidis, Nicholas; Briassoulis, E. Ch; Fountzilas, George (1996)

Purpose: To investigate if double modulation of fluorouracil (5-FU) with leucovorin (folinic acid [FA]) and interferon alfa-2b (IFN 2b) improves responses and survival in comparison to single modulation of 5-FU with FA. ...